News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA: Novartis Corporation (NVS)'s Osteoporosis Drug Reclast Raises Kidney Failure Risk


9/2/2011 7:26:51 AM

The FDA warns that the osteoporosis drug Reclast (zoledronic acid) raises the risk of kidney failure. The warning is targeted at patients who already suffer from kidney impairment. It's also aimed at those who are taking potentially kidney-damaging (nephrotoxic) medications or diuretics at the same time as Reclast. According to the new warning, Reclast-induced kidney failure can also occur among severely dehydrated patients. Older patients with kidney impairment are at heightened risk of kidney failure. The FDA warning says that kidney failure is a rare but serious complication for at-risk patients taking Reclast. The drug was approved in April 2007.

Read at WebMD
Read at Wall Street Journal
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES